Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 4/20 | 0.43 |
| ▸ | CTSK | P43235 | 14/20 | 0.40 |
| ▸ | CTSS | P25774 | 12/20 | 0.40 |
| ▸ | CTSB | P07858 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CTSD | P07339 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3370066 | 0.94 | CTSL (0.41) | CTSLCTSKCTSSCTSB | |
| SCHEMBL22765979 | 0.92 | P2RX7 (0.41) | CTSLCTSKCTSSCTSBMEN1 | |
| SCHEMBL23276791 | 0.90 | CTSL (0.39) | CTSLCTSKCTSSCTSBCTSD | |
| SCHEMBL23299665 | 0.88 | CTSL (0.38) | CTSLCTSKCTSSCTSBCTSD | |
| SCHEMBL27648998 | 0.86 | JAK2 (0.37) | CTSLCTSKCTSSCTSBCTSD | |
| SCHEMBL15295679 | 0.83 | CTSL (0.37) | CTSLCTSKCTSSMEN1MAPK1 | |
| SCHEMBL4418580 | 0.83 | JAK2 (0.39) | MEN1KMT2A | |
| SCHEMBL6017523 | 0.81 | CTSL (0.36) | CTSLCTSKCTSSCTSBCTSD | |
| SCHEMBL20289489 | 0.80 | CTSL (0.40) | CTSLCTSKCTSSCTSBMEN1 | |
| SCHEMBL15297512 | 0.79 | MEN1 (0.37) | CTSLCTSKCTSSMEN1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260042788-A1 | STAT6 COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-02-12 | — | — | US | disclosed |
| US-20250163022-A1 | PARP1 INHIBITORS | SYNNOVATION THERAPEUTICS, INC. | 2025-05-22 | — | — | US | disclosed |
| CN-119431365-A | Phenyl heterocyclic derivative-containing regulator and preparation method and application thereof | 江苏豪森药业集团有限公司 | 2025-02-14 | — | — | CN | disclosed |
| WO-2025026270-A1 | BENZO NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE REGULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翰森生物医药科技有限公司 | 2025-02-06 | — | — | WO | disclosed |
| EP-4452963-A1 | PARP1 INHIBITORS | Synnovation Therapeutics, Inc. (US) | 2024-10-30 | — | — | EP | disclosed |
| US-20240294523-A1 | HETEROCYCLIC LACTAM COMPOUND, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2024-09-05 | — | — | US | disclosed |
| WO-2023122140-A1 | PARP1 INHIBITORS | SYNNOVATION THERAPEUTICS, INC. (US) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023122140-A1 | PARP1 INHIBITORS | SYNNOVATION THERAPEUTICS, INC. (US) | 2023-06-29 | — | — | WO | disclosed |
| WO-2022258052-A1 | HETEROCYCLIC LACTAM COMPOUND, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | 劲方医药科技(上海)有限公司 | 2022-12-15 | — | — | WO | disclosed |
| WO-2022258052-A1 | HETEROCYCLIC LACTAM COMPOUND, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | 劲方医药科技(上海)有限公司 | 2022-12-15 | — | — | WO | disclosed |
| WO-2019154261-A1 | PYRIDINE DERIVATIVE RELATED TO KMD5 PATHWAY | 南京明德新药研发股份有限公司 | 2019-08-15 | — | — | WO | disclosed |
| US-9777020-B2 | Furo-3-carboxamide derivatives and methods of use | ABBVIE INC. (US) | 2017-10-03 | — | — | US | disclosed |
| US-20150210720-A1 | FURO-3-CARBOXAMIDE DERIVATIVES AND METHODS OF USE | ABBVIE INC. | 2015-07-30 | — | — | US | disclosed |
| EP-1170281-A1 | 1,1- and 1,2-disubstituted cyclopropanes, process for their preparation and pharmaceutical compositions thereof | LES LABORATOIRES SERVIER (FR) | 2002-01-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260042788-A1 | STAT6 COMPOUNDS | STAT6, IL6ST, NFATC1 | CTSL 2153/4885CTSK 2215/4885CTSS 3223/4885 |
| US-20240294523-A1 | HETEROCYCLIC LACTAM COMPOUND, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | RIPK1, RIPK4, RIPK3 | CTSL 742/4885CTSK 271/4885CTSS 1307/4885 |
| US-20250163022-A1 | PARP1 INHIBITORS | PARP1, PARP11, PARP12 | CTSL 2475/4885CTSK 1683/4885CTSS 2097/4885 |
| US-20150210720-A1 | FURO-3-CARBOXAMIDE DERIVATIVES AND METHODS OF USE | NTRK2, MUSK, NTRK3 | CTSL 827/4885CTSK 87/4885CTSS 249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.